Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial

References

• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234. doi:10.1056/NEJM199807233390404
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696. doi:10.1016/S0140-6736(04)16895-5
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists C, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi:10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438–445. doi:10.1016/j.jacc.2006.04.070
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–3421. doi:10.1161/circ.106.25.3143
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi:10.1093/eurheartj/ehw272
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement1):S103–S123.
   PubMedGoogle Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87. doi:10.4158/EP171764.APPGL
   PubMed Web of Science ®Google Scholar
• 2016 RCPT dyslipidemia clinical practice guideline on pharmacological therapy of dyslipidemia for atherosclerosis cardiovascular disease prevention. Available from: http://www.thaiheart.org/Download/2016-RCPT-Dyslipidemia-Guideline.html. Accessed January 18, 2020.
   Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25Pt B):2889–2934. doi:10.1016/j.jacc.2013.11.002
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e1143.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S86–S104. doi:10.2337/dc18-S009
   PubMedGoogle Scholar
• Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99(3):410–414. doi:10.1016/j.amjcard.2006.08.051
   PubMed Web of Science ®Google Scholar
• Wang P. Statin dose in Asians: is pharmacogenetics relevant? Pharmacogenomics. 2011;12(11):1605–1615. doi:10.2217/pgs.11.98
   PubMed Web of Science ®Google Scholar
• Lee B, Dumrongkitchaiporn K, Sriussadaporn S. Thongtang N statin intensity regimens in Thai type 2 diabetic patients who achieved LDL-C targets. J Med Assoc Thai. 2017;100(5):603–611.
   Google Scholar
• Thongtang N, Sitthananun C, Sriussadaporn S, Nitiyanant W. Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients. J Diabetes Metab Disord. 2017;16:6. doi:10.1186/s40200-017-0290-x
   PubMedGoogle Scholar
• Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78(4):330–341. doi:10.1016/j.clpt.2005.06.013
   PubMed Web of Science ®Google Scholar
• Poh KK, Ambegaonkar B, Baxter CA, et al. Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. Eur J Prev Cardiol. 2018;25(18):1950–1963. doi:10.1177/2047487318798927
   PubMedGoogle Scholar
• Ye P. The Chinese dose of statin. Cardiol Plus 2016;1(4):1–5.
   Google Scholar
• Chan JC, Kong AP, Bao W, Fayyad R, Laskey R. Safety of atorvastatin in Asian patients within clinical trials. Cardiovasc Ther. 2016;34(6):431–440. doi:10.1111/1755-5922.12214
   PubMedGoogle Scholar
• Li DQ, Kim RB, McArthur E, et al. Statin safety in Chinese: a population-based study of older adults. PLoS One. 2016;11(3):e0150990. doi:10.1371/journal.pone.0150990
   PubMedGoogle Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564. doi:10.1001/jama.2011.860
   PubMed Web of Science ®Google Scholar
• Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N, The Diabetes Subpanel of the National Lipid Association Expert P. An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S17–S29. doi:10.1016/j.jacl.2014.02.012
   PubMed Web of Science ®Google Scholar
• Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–2539. doi:10.1093/eurheartj/ehy182
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559.
   PubMed Web of Science ®Google Scholar
• Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation. 2009;119(16):2136–2145. doi:10.1161/CIRCULATIONAHA.108.795666
   PubMedGoogle Scholar
• Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97(1):61–67. doi:10.1016/j.amjcard.2005.07.108
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–1163. doi:10.1016/S0140-6736(06)69472-5
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41(1):111–188.
   Web of Science ®Google Scholar
• Jones P, Davidson M, Stein E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol. 2003;92(2):152–160. doi:10.1016/S0002-9149(03)00530-7
   PubMed Web of Science ®Google Scholar
• Adams S, Tsang M, Wright J. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;(3):CD008226. doi:10.1002/14651858.CD008226.pub3
   PubMedGoogle Scholar